Mankind Pharma Stock Price - ₹2,368.80 | Healthcare

‌
‌
‌

The Quarter story

The two most recent quarterly results, compared side-by-side.

Mankind Pharma delivers robust revenue growth and margin expansion alongside steady debt reduction, with strong domestic and export traction offsetting minor pressures in select therapy segments.

Consolidated revenue grows from ₹3,443 Cr in Q4 FY26 to ₹4,031 Cr in Q1 FY27, driven by strong domestic and export demand

Working capital days with the BSV acquisition rise from 46 in Q2 FY26 to 52 in Q1 FY27, indicating integration-related cash cycle pressure

Net debt falls from ₹5,249 Cr in Q1 FY26 to ₹3,377 Cr in Q1 FY27, improving the debt-to-EBITDA ratio to 0.9x

Anti-diabetic outperformance declines from 1.6x in Q1 FY26 to 1.1x in Q1 FY27, suggesting a moderating competitive edge in the segment

EBITDA margin expands from 23.8% in Q1 FY26 to 26.3% in Q1 FY27, reflecting effective cost control and pricing power

Cardiac outperformance falls from 1.5x in Q1 FY26 to 1.1x in Q1 FY27, reflecting narrowing growth lead against peers

Export revenue climbs from ₹469 Cr in Q1 FY26 to ₹605 Cr in Q1 FY27, maintaining a steady 15% share of total sales

Consumer healthcare EBITDA margin eases from 21.4% in Q4 FY26 to 18.6% in Q1 FY27, pointing to seasonal volume mix shifts

Consumer healthcare digital share grows from 11% in Q1 FY26 to 15% in Q1 FY27, signaling successful omnichannel penetration

‌
‌
‌

In the news

Mankind Pharma shares down 0.25% despite China insulin partnership

Mankind Pharma Q1 FY27: Margin Magic and Chronic Growth Drive 29% Profit Surge

Motilal Oswal maintains ₹2975 target for Mankind Pharma

Makind Pharma Q1 profit surges 29% to ₹574 crore on strong domestic growth

RBL Bank, PG Electroplast, Mankind Pharma: 3 stocks for F&O trading

4 Pharma Giants Pivot to Chronic Care for Growth

Mankind Pharma divests Broadway Hospitality for ₹49 cr, plans €5M Netherlands SPV

Mankind Pharma Q2 results: 16.79% EPS growth, stock buy recommendation

Ather Energy Surges 5.5% on Delhi EV Policy 2.0 Boost

Govt tightens cough syrup rules, pharma stocks fall up to 1.11%

Mankind Pharma drops 5th straight session, down 0.47%

Mankind Pharma Q4 PAT jumps 32% to ₹554 cr, beats estimates

Mankind Pharma rises for fifth straight session, up 2.96%

Rupee hits 95, crude at $120+: Markets face storm warnings

How War in West Asia Is Squeezing India's Condom Industry

Morgan Stanley initiates Overweight rating on Mankind Pharma with ₹2,500 target

Mankind Pharma shares rise 3% on Rivotril brand acquisition

Mankind Pharma Q3 profit up 7.50% to ₹408.75 cr

Mankind Pharma Q3 Results: PAT up 9.5% to ₹414 crore, shares gain 4%

About the company